title: A comment on "The risky business of assessing research risk".
authors.forename: Nicole
authors.initials: N
authors.lastname: Glaser
authors.forename: Nathan
authors.initials: N
authors.lastname: Kuppermann
authors.forename: James
authors.initials: J
authors.lastname: Marcin
authors.forename: Walton O
authors.initials: WO
authors.lastname: Schalick
mesh_terms: D000208:Acute Disease; D001929:Brain Edema / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D002648:Child; D003422:Critical Care / Q000941:ethics; D016883:Diabetic Ketoacidosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D028744:Ethics Committees, Research; D006805:Human Experimentation / Q000941:ethics*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage*; D015278:Intensive Care Units, Pediatric / Q000941:ethics; D008279:Magnetic Resonance Imaging / Q000941:ethics; D018570:Risk Assessment
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin